MedTrace Logo

Phase II Study of the Effect of CK-1827452 Injection on Myocardial Efficiency

NCT00748579 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 2

Last updated 2020-01-21

Study results available
· View outcomes & findings →

Summary

The purpose for this study (CY 1124) is to evaluate the effects of CK-1827452, a cardiac myosin activator, on myocardial systolic performance, myocardial oxygen consumption, and myocardial efficiency in patients with heart failure and to confirm that the unique preclinical pharmacological profile of CK- 1827452 is substantially the same in patients with heart failure.

Conditions

Interventions

DRUG

CK-1827452

I.V. infusion for 0.5 hour at 54mg/hr followed by 1 hour at 21mg/hr

DRUG

CK-1827452

I.V. infusion for ≤ 1 hour at 72mg/hr followed by 1 hour at 36mg/hr

Sponsors & Collaborators

  • Cytokinetics

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2008-11-30
Completion
2009-07-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00748579 on ClinicalTrials.gov